ORIGINAL ARTICLE: In Vitro and In Vivo Studies Evaluating Recombinant Plasmid pCXN2-mIzumo as a Potential Immunocontraceptive Antigen
Article first published online: 12 FEB 2009
© 2009 John Wiley & Sons A/S
American Journal of Reproductive Immunology
Volume 61, Issue 3, pages 227–235, March 2009
How to Cite
An, G., Huang, T.-H., Wang, D.-G., Xie, Q.-D., Ma, L. and Chen, D.-Y. (2009), ORIGINAL ARTICLE: In Vitro and In Vivo Studies Evaluating Recombinant Plasmid pCXN2-mIzumo as a Potential Immunocontraceptive Antigen. American Journal of Reproductive Immunology, 61: 227–235. doi: 10.1111/j.1600-0897.2009.00685.x
- Issue published online: 12 FEB 2009
- Article first published online: 12 FEB 2009
- Submitted December 5, 2008; accepted January 5, 2009.
- Genetic immunization;
Problems Study on feasibility of pCXN2-mIzumo as a potential immunocontraceptive antigen.
Method of study Two groups of mice received 100 μg/mouse plasmids of pCXN2-mIzumo and pCXN2 respectively. RT-PCR Immunofluorescence assay and ELISA were performed to observe pCXN2-mIzumo expression and antibody response in the inoculated mice. Sperm penetration assay and animal mating were employed to detect differences of in vitro fertilization (IVF) rate and mean litter size between the experimental and control groups.
Results Izumo cDNA positive bands were detected in sample from mice immunized with pCXN2-mIzumo. IgG response started to rise at 2 weeks after first boost and reached the highest antibody titers at 2 weeks after third boost of immunization with pCXN2-mIzumo in the experimental mice. In vitro fertilization rate in the experimental group (11.57%) was significantly lower than that in control (36.60%). Significant difference of mean litter size between female experimental and control groups was observed, and there was significant negative correlation between individual anti-serum titers and litter size (r = −0.308, P < 0.05).
Conclusion pCXN2-mIzumo plasmid possesses appreciable anti-fertility potential.